argenx advances clinical development of agonist antibody for myasthenic syndromes

ARGX-119 is the sixth molecule developed through our Immunology Innovation Program to show proof-of-concept

Novo Nordisk to advance subcutaneous and oral amycretin for weight management into phase 3 clinical development

The decision to advance subcutaneous and oral amycretin into phase 3 is based on feedback received from regulatory authorities

Mezzion secures $20 million funding to advance Phase 3 clinical development of Udenafil for fontan patients

Parexel appoints Gwyn Bebb to lead oncology clinical development

Appointment further strengthens company’s expertise in fastest-growing therapeutic area to meet patient need

Boehringer Ingelheim begins clinical development for fibrotic diseases

‘Fibrotic disease’ is a term that covers a range of diseases characterized by uncontrolled and progressive fibrosis,

Cytel unlocks innovative clinical development expertise for APAC biopharma sector

Cytel has now established entities in Australia, Shanghai, Beijing, and Singapore, and plans to expand into Seoul and Tokyo in the coming years.

Sanofi updates on amcenestrant clinical development program

The decision is based on the outcome of a prespecified interim analysis of the Phase 3 AMEERA-5 trial

Cellenkos scores FDA orphan drug designation for CK0804 in rare blood cancer

Receiving Orphan Drug Designation is an important milestone in the clinical development of CK0804 for myelofibrosis

Amgen snaps up UK biotech Dark Blue Therapeutics in up to $840m oncology deal

The privately held biotech brings a first-in-class oncology program focused on small molecule–targeted protein degradation

Ascletis Pharma gets FDA nod for Phase II diabetes trial of oral GLP-1 drug

The trial’s primary endpoint is the mean change in HbA1c from baseline, while secondary endpoints include changes in fasting blood glucose, body weight, and overall safety